No connection

Search Results

XWEL

BEARISH
$1.14 Live
XWELL, Inc. · NASDAQ
$0.26 52W Range $2.2
Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 24, 2026
Market cap
$9.04M
P/E
N/A
ROE
N/A
Profit margin
-58.2%
Debt/Equity
N/A
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
95%
XWEL exhibits severe financial distress, anchored by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -1.04, indicating negative shareholder equity. The company is facing a liquidity crisis with a Current Ratio of 0.46 and a Quick Ratio of 0.33, suggesting it cannot meet its short-term obligations. While there has been a speculative 1-year price recovery and recent EPS 'beats,' these are relative to deeply negative expectations and do not offset the fundamental insolvency risks. The combination of declining revenue (-4.20% YoY) and negative margins makes the current valuation unsustainable.

Key Strengths

Low Price-to-Sales ratio (0.31) suggests the market has already priced in significant failure
Recent quarterly EPS surprises have been positive (beating negative estimates)
Short-term 1-year price performance shows speculative interest (+48%)
Gross margin remains positive at 25.70%
Recent Q/Q EPS growth shows a reduction in losses

Key Risks

Extreme bankruptcy risk indicated by Piotroski F-Score of 1/9
Negative equity (P/B -1.04) indicates liabilities exceed assets
Severe liquidity shortage with a Current Ratio well below 1.0 (0.46)
Negative revenue growth (-4.20% YoY) in a competitive healthcare sector
Deeply negative profit margins (-58.17%) and operating margins

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
10
Weak
Value
10
Future
20
Past
15
Health
5
Dividend
0
AI Verdict
High Risk / Distressed
Key drivers: Negative Equity, Liquidity Crisis, Piotroski F-Score 1/9, Declining Revenue
Confidence
90%
Value
10/100

P/B of -1.04 renders traditional value metrics meaningless.

Positives
  • Very low P/S ratio
Watchpoints
  • Negative P/B ratio
  • No Graham Number possible due to negative earnings/equity
Future
20/100

Revenue growth is -4.20%, contradicting the growth needed for a turnaround.

Positives
  • Reduction in quarterly loss magnitude
Watchpoints
  • Negative YoY revenue growth
  • Lack of analyst coverage
Past
15/100

Long-term trend is overwhelmingly bearish.

Positives
  • Recent 1-year price bounce
Watchpoints
  • 5-year price collapse of -96%
  • Consistent history of negative earnings
Health
5/100

Financial health is critical; company is technically insolvent.

Positives
No standout positives identified.
Watchpoints
  • Piotroski F-Score 1/9
  • Current Ratio 0.46
  • Negative Equity
Dividend
0/100

Dividend strength is 0/100.

Positives
No standout positives identified.
Watchpoints
  • No dividend paid
  • No capacity to pay

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$1.14

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for XWEL and closest competitors.

Updated 2026-04-23
XWE
XWELL, Inc.
Primary
5Y
-96.0%
3Y
-79.6%
1Y
+48.0%
6M
+18.8%
1M
-15.6%
1W
+9.6%
TNO
Tenon Medical, Inc.
Peer
5Y
-100.0%
3Y
-99.5%
1Y
-28.8%
6M
-37.7%
1M
-0.6%
1W
-2.7%
AMS
American Shared Hospital Services
Peer
5Y
-46.8%
3Y
-52.8%
1Y
-51.6%
6M
-41.2%
1M
-29.5%
1W
-10.7%
NOT
Inotiv, Inc.
Peer
5Y
-98.8%
3Y
-95.0%
1Y
-84.2%
6M
-82.6%
1M
-31.9%
1W
-2.0%
SIL
Silo Pharma, Inc.
Peer
5Y
-96.0%
3Y
-78.0%
1Y
-52.1%
6M
-8.0%
1M
+60.9%
1W
+16.8%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
-0.43
PEG Ratio
N/A
P/B Ratio
-1.04
P/S Ratio
0.31
EV/Revenue
0.98
EV/EBITDA
-3.37
Market Cap
$9.04M

Profitability

Profit margins and return metrics

Profit Margin -58.17%
Operating Margin -45.07%
Gross Margin 25.7%
ROE N/A
ROA -31.98%

Growth

Revenue and earnings growth rates

Revenue Growth -4.2%
Earnings Growth N/A
Q/Q Revenue Growth -4.19%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
N/A
Current Ratio
0.46
Weak
Quick Ratio
0.33
Poor
Cash/Share
$0.33

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Gross Margin
40.8%
Op. Margin
-45.1%
Net Margin
-129.7%
Total Assets
$0.0B
Liabilities
$0.0B
Equity
$-0.0B
Debt/Equity
-1.08x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
1781%

Quarterly Earnings History

EPS performance vs analyst estimates

2023-11-14
$-0.77
+4.3% surprise
2023-08-14
$-1.37
+2.1% surprise
2023-05-15
$-1.3
+50.0% surprise
2023-04-17
$-1.75
-9.1% surprise

Healthcare Sector Comparison

Comparing XWEL against 528 companies in the Healthcare sector (28 bullish, 156 neutral, 344 bearish)
Profit Margin
-58.17%
This Stock
vs
-16.56%
Sector Avg
+251.3% (Superior)
Revenue Growth
-4.2%
This Stock
vs
131.76%
Sector Avg
-103.2% (Slower)
Current Ratio
0.46
This Stock
vs
4.62
Sector Avg
-90.1% (Weaker)

Similar Companies

Peer comparison within the same industry

XWEL XWELL, Inc.
BEARISH
Mkt Cap
$9M
P/E
-
ROE
-%
Price
$1.14
TNON Tenon Medical, Inc.
BEARISH
Mkt Cap
$9M
P/E
-
ROE
-228.1%
Price
$0.8
 Compare with XWEL
AMS American...
BEARISH
Mkt Cap
$9M
P/E
-
ROE
-9.4%
Price
$1.33
 Compare with XWEL
NOTV Inotiv, Inc.
BEARISH
Mkt Cap
$8M
P/E
-
ROE
-49.8%
Price
$0.24
 Compare with XWEL
SILO Silo Pharma, Inc.
BEARISH
Mkt Cap
$8M
P/E
-
ROE
-74.6%
Price
$0.52
 Compare with XWEL

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

LEBOWITZ MICHAEL
Director
Stock Award
2026-02-27
100,000 shares
ERNST EZRA
Chief Executive Officer
Stock Award
2026-02-27
100,000 shares
WIZENBERG GAEELLE SANDRA
Director
Stock Award
2026-02-27
100,000 shares
WEINSTEIN ROBERT
Director
Stock Award
2026-02-27
100,000 shares
BERNSTEIN BRUCE G
Director
Stock Award
2026-02-27
100,000 shares
Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

8-K/A
8-K/A
2026-04-10

XWEL filed an amendment to a previously submitted Form 8-K on April 10, 2026.

8-K
FORM 8-K
2026-04-01
10-K
10-K
2026-04-01

XWEL filed its annual 10-K report on April 1, 2026. Due to the absence of detailed text in the provided excerpts, specific financial highlights and risk factors cannot be determined.

8-K
FORM 8-K
2026-03-04

XWEL filed an 8-K on March 4, 2026, likely to announce its year-end financial results.

8-K
FORM 8-K
2026-02-25

XWEL filed an 8-K on February 25, 2026, likely to report its annual financial results or announce its annual meeting of shareholders.

8-K
FORM 8-K
2025-12-18
8-K
FORM 8-K
2025-12-05
DEF 14A
FORM DEF 14A
2025-11-17

XWEL filed a definitive proxy statement (DEF 14A) on November 17, 2025, to provide shareholders with information required for voting at an upcoming meeting.

10-Q
10-Q
2025-11-14
8-K
FORM 8-K
2025-11-14

XWEL filed an 8-K on November 14, 2025, likely to report its third-quarter financial results.

8-K
FORM 8-K
2025-11-14

XWEL filed an 8-K on November 14, 2025, likely to report its third-quarter financial results.

8-K
FORM 8-K
2025-11-07
8-K
FORM 8-K
2025-11-04
8-K
FORM 8-K
2025-10-09
8-K
FORM 8-K
2025-09-17
Data sourced from SEC EDGAR. AI summaries generated automatically.

Past News Coverage

Recent headlines mentioning XWEL from our newsroom.

Newest → oldest
Back to All Stocks
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile